Cost Is the Biggest Barrier to Exxua XR Adherence — Here's How Providers Can Help

You've made the clinical decision to prescribe Exxua XR (Gepirone) for a patient with major depressive disorder. Maybe they've failed multiple SSRIs, maybe they couldn't tolerate the sexual side effects, or maybe Exxua XR's unique mechanism of action makes it the right fit. The clinical reasoning is solid.

Then your patient calls back: "My pharmacy says it's $1,800. I can't afford that."

This is the reality of prescribing a newly launched brand-name antidepressant in 2026. Exxua XR has no generic equivalent, limited insurance formulary coverage, and a retail price that puts it out of reach for many patients. As a prescriber, you're in a unique position to help patients navigate the cost landscape — and keeping cost in the conversation is essential to treatment adherence.

This guide provides a practical overview of every savings lever available for Exxua XR, plus strategies for building cost conversations into your workflow.

What Patients Are Actually Paying

Let's start with the numbers:

• Retail cash price: $1,500 to $1,800 per month for 30 tablets (varies by strength; the 72.6 mg dose runs approximately $1,787 for 30 tablets)
• Generic available: No. Gepirone has NCE exclusivity through September 2028.
• Insurance coverage: Expanding but inconsistent. Most commercial and Medicare Part D plans that cover Exxua XR require prior authorization and/or step therapy (typically trial and failure of generic SSRIs or SNRIs first).
• Formulary tier: When covered, expect non-preferred brand tier placement with higher copays, similar to Auvelity and other newer branded antidepressants.

The bottom line: even insured patients may face significant out-of-pocket costs, and uninsured patients are looking at a price point that's simply not feasible without assistance.

Manufacturer Savings Programs

Aytu RxConnect Program

Aytu BioPharma's primary savings vehicle for Exxua XR is the Aytu RxConnect Program. Key details for providers:

• Available through a network of over 1,000 participating pharmacies
• Primarily independent and specialty pharmacies — not available at major retail chains like CVS, Walgreens, or Rite Aid
• Eligible patients may receive reduced pricing on Exxua XR
• Enrollment details and eligibility criteria are available through Aytu BioPharma's website or sales representatives

The limited pharmacy network is the primary friction point. Patients accustomed to filling prescriptions at their usual chain pharmacy will need to use an RxConnect participating location. This is important to communicate at the point of prescribing — not after the patient has already been turned away.

Prior Authorization Support Program

Aytu also offers a Prior Authorization Support Program designed to assist prescribers with the PA process. Given that most payers require PA for Exxua XR, this is worth leveraging:

• Support with completing PA paperwork
• Clinical documentation templates and payer-specific guidance
• Appeals support if initial PA is denied

Proactive PA submission at the time of prescribing (rather than waiting for a rejection at the pharmacy) significantly reduces delays in patient access. For more on the clinical and coverage landscape, see our provider guide to the Exxua XR shortage.

Coupon and Discount Cards

Prescription discount cards and coupon platforms can sometimes reduce costs for patients paying cash. Here's what's currently available for Exxua XR:

Major Coupon Platforms

• GoodRx, SingleCare, RxSaver, Optum Perks, BuzzRx — These platforms aggregate pharmacy pricing and may show discounted prices at participating locations. For a brand-name drug without a generic, the discounts may be modest, but they're worth checking.
• Inside Rx — Specifically focused on brand-name medications and may offer better pricing for newer drugs.

Important Caveats for Providers

• Coupon card pricing fluctuates and varies by pharmacy
• Discount cards cannot be combined with insurance (patients use one or the other at the pharmacy)
• For a $1,500-$1,800/month medication, a 10-15% coupon discount still leaves most patients with an unaffordable bill
• Coupon cards are most useful as a bridge — not a long-term solution — while insurance coverage or manufacturer support is being arranged

Direct patients to our patient-facing savings guide for the full list of coupon and discount resources.

Generic Alternatives and Therapeutic Substitution

When cost is prohibitive and savings programs aren't sufficient, it's worth discussing alternative treatments with your patient:

No Generic Gepirone Available

Exxua XR has NCE exclusivity through September 2028, and no generic is expected before then. Unlike many medication categories, there's no generic equivalent to switch to.

Therapeutic Alternatives to Consider

If cost makes Exxua XR inaccessible, these alternatives may be appropriate depending on clinical context:

• Buspirone (Buspar): Same azapirone class, FDA-approved for anxiety, used off-label for depression augmentation. Available as a low-cost generic ($4-$15/month). Not a direct substitute — it's not proven as monotherapy for MDD — but it's the closest pharmacological relative.
• Bupropion (Wellbutrin): Generic available, low risk of sexual side effects and weight gain, widely covered. Different mechanism (NDRI) but addresses some of the same patient concerns that drive Exxua XR prescribing.
• Auvelity (Dextromethorphan-Bupropion): Newer branded antidepressant, different mechanism (NMDA modulation), also expensive but may have better formulary coverage in some plans.
• Spravato (Esketamine): For treatment-resistant depression, administered in-office, covered by many plans for appropriate patients.

For a detailed comparison, refer to our alternatives to Exxua XR article, which you can share with patients.

Patient Assistance Programs

For patients experiencing financial hardship — particularly those who are uninsured or underinsured — patient assistance programs (PAPs) may provide Exxua XR at reduced or no cost:

• Aytu BioPharma direct assistance: Contact Aytu BioPharma to inquire about financial hardship programs. As a newly launched product, specific PAP details are evolving.
• NeedyMeds.org: Comprehensive database of patient assistance programs, including manufacturer programs, state programs, and disease-specific foundations.
• RxAssist.org: Another resource for locating PAPs by medication or manufacturer.
• RxHope.com: Connects patients directly with manufacturer assistance applications.

Provider Role in PAP Access

Most PAPs require provider involvement:

• Completing a prescription or enrollment form
• Providing clinical documentation of diagnosis and treatment history
• Attesting to the patient's financial situation (some programs require income verification)

Designating a staff member to manage PAP applications can streamline this process. The upfront time investment pays dividends in patient retention and adherence.

Building Cost Conversations into Your Workflow

The most impactful thing you can do as a prescriber is address cost proactively — before the patient hits the pharmacy counter. Here's a practical workflow:

At the Point of Prescribing

1. Mention cost upfront: "Exxua XR is a newer medication without a generic, so it can be expensive. Let's make sure we have a plan to manage the cost."
2. Check insurance coverage: Have your team verify formulary status and PA requirements before the patient leaves.
3. Submit PA proactively: Don't wait for a rejection. Submit the prior authorization at the time of prescribing using Aytu's PA Support Program resources.
4. Provide pharmacy guidance: Tell patients that Exxua XR is available through the Aytu RxConnect network and may not be at their usual pharmacy. Give them the tools to find participating pharmacies — including Medfinder for Providers.

At Follow-Up

1. Confirm the patient filled the prescription: Cost-related non-fill is extremely common with branded medications. Ask directly.
2. Troubleshoot barriers: If they haven't filled, identify the barrier (cost, pharmacy access, PA denial) and address it.
3. Reassess periodically: Insurance formularies change. A medication not covered in Q1 may be added by Q3. Revisit coverage periodically.

Staff Training

Consider training your front-office or clinical support staff on:

• How to check insurance formularies for Exxua XR
• How to initiate and track PA requests
• How to direct patients to the Aytu RxConnect Program and discount card resources
• How to complete PAP applications

A designated "prescription access coordinator" role — even if informal — dramatically reduces the prescriber burden and improves patient outcomes.

Final Thoughts

Exxua XR fills a genuine clinical need — it's the first azapirone antidepressant, with a differentiated side effect profile that matters for patients who've struggled with SSRIs. But clinical efficacy means nothing if patients can't afford to fill the prescription.

As prescribers, we can't control drug pricing. But we can control how proactively we address it. Submitting PAs early, connecting patients with manufacturer programs, knowing when to consider therapeutic alternatives, and simply asking "were you able to fill your prescription?" at every follow-up — these are high-impact, low-effort interventions that keep patients on effective treatment.

The savings landscape for Exxua XR will continue evolving throughout 2026 as more payers add formulary coverage. Stay connected with Aytu BioPharma's prescriber resources and check Medfinder for Providers for the latest availability and access tools.